2019; Gao et al. 2020). TP intervention disrupts this cascade. In a NZB/W F1 murine model of lupus, 15 μg/kg TP treatment reduced the production of TNF-α, IL-6, and CCL2, leading to improved renal outcomes and extended survival (Tao et al. 2008). Mechanistically, TP inhibits interferon-gamma (IFN-γ), thereby blocking the downstream JAK/STAT1 signaling pathway and suppressing the expression of the key chemokine CXCL10 in glomerular cells, which curtails leukocyte recruitment (Shi et al. 2023). Here, IFNG is linked to systemic lupus erythematosus.